Treatment of CT26, MC38, mouse triple-negative breast cancer 4T1, and mouse pancreatic cancer Pan18 with LB100 induced MLH1 loss and an increase in MSI status (Supplementary Fig. 7). This evidence concerns the gene DDX53 and pancreatic neoplasm.